Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring

D. Crivellari, D. Lombardi, G. Corona, C. Massacesi, R. Talamini, R. Sorio, M. D. Magri, C. Lestuzzi, A. Lucenti, A. Veronesi, G. Toffoli

Research output: Contribution to journalArticle

Abstract

Background: To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Patients and methods: Elderly women (≥65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks. After the first fourteen patients, due to excessive toxicity, the protocol was amended to 5 mg/day. IDA and Idarubicinol (IDOL) plasma concentrations (Ctrough) were investigated in all patients. Results: Between April 1999 and June 2004, 47 elderly patients were accrued in this two-part study (14 and 33 patients respectively). The median age was 74 and 75 years respectively. Visceral involvement was present in most patients. A partial response was noted in 7/31 patients (22%; 95% CI, 9.6-41.1%). Eleven patients had stable disease (33%). At the dose of 5 mg/day the treatment was well tolerated. Neutropenia grade 4 was present in only 6% of patients; alopecia > grade 1 and cardiotoxicity did not occur. The median time to progression was 3 months and the median overall survival was 17 months. IDA Ctrough and IDOL Ctrough levels were significantly associated with haematologic toxicity. Conclusion: This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. A determination of the IDA and IDOL plasma levels (Ctrough) is predictive for toxicity.

Original languageEnglish
Pages (from-to)807-812
Number of pages6
JournalAnnals of Oncology
Volume17
Issue number5
DOIs
Publication statusPublished - May 2006

Fingerprint

Idarubicin
Drug Monitoring
Appointments and Schedules
Pharmacokinetics
Breast Neoplasms
Alopecia
Neutropenia

Keywords

  • Elderly breast cancer patients
  • Oral idarubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer : Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. / Crivellari, D.; Lombardi, D.; Corona, G.; Massacesi, C.; Talamini, R.; Sorio, R.; Magri, M. D.; Lestuzzi, C.; Lucenti, A.; Veronesi, A.; Toffoli, G.

In: Annals of Oncology, Vol. 17, No. 5, 05.2006, p. 807-812.

Research output: Contribution to journalArticle

Crivellari, D. ; Lombardi, D. ; Corona, G. ; Massacesi, C. ; Talamini, R. ; Sorio, R. ; Magri, M. D. ; Lestuzzi, C. ; Lucenti, A. ; Veronesi, A. ; Toffoli, G. / Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer : Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. In: Annals of Oncology. 2006 ; Vol. 17, No. 5. pp. 807-812.
@article{de2ee90aec93465da94cdf12591b5801,
title = "Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring",
abstract = "Background: To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Patients and methods: Elderly women (≥65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks. After the first fourteen patients, due to excessive toxicity, the protocol was amended to 5 mg/day. IDA and Idarubicinol (IDOL) plasma concentrations (Ctrough) were investigated in all patients. Results: Between April 1999 and June 2004, 47 elderly patients were accrued in this two-part study (14 and 33 patients respectively). The median age was 74 and 75 years respectively. Visceral involvement was present in most patients. A partial response was noted in 7/31 patients (22{\%}; 95{\%} CI, 9.6-41.1{\%}). Eleven patients had stable disease (33{\%}). At the dose of 5 mg/day the treatment was well tolerated. Neutropenia grade 4 was present in only 6{\%} of patients; alopecia > grade 1 and cardiotoxicity did not occur. The median time to progression was 3 months and the median overall survival was 17 months. IDA Ctrough and IDOL Ctrough levels were significantly associated with haematologic toxicity. Conclusion: This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. A determination of the IDA and IDOL plasma levels (Ctrough) is predictive for toxicity.",
keywords = "Elderly breast cancer patients, Oral idarubicin",
author = "D. Crivellari and D. Lombardi and G. Corona and C. Massacesi and R. Talamini and R. Sorio and Magri, {M. D.} and C. Lestuzzi and A. Lucenti and A. Veronesi and G. Toffoli",
year = "2006",
month = "5",
doi = "10.1093/annonc/mdl013",
language = "English",
volume = "17",
pages = "807--812",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer

T2 - Comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring

AU - Crivellari, D.

AU - Lombardi, D.

AU - Corona, G.

AU - Massacesi, C.

AU - Talamini, R.

AU - Sorio, R.

AU - Magri, M. D.

AU - Lestuzzi, C.

AU - Lucenti, A.

AU - Veronesi, A.

AU - Toffoli, G.

PY - 2006/5

Y1 - 2006/5

N2 - Background: To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Patients and methods: Elderly women (≥65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks. After the first fourteen patients, due to excessive toxicity, the protocol was amended to 5 mg/day. IDA and Idarubicinol (IDOL) plasma concentrations (Ctrough) were investigated in all patients. Results: Between April 1999 and June 2004, 47 elderly patients were accrued in this two-part study (14 and 33 patients respectively). The median age was 74 and 75 years respectively. Visceral involvement was present in most patients. A partial response was noted in 7/31 patients (22%; 95% CI, 9.6-41.1%). Eleven patients had stable disease (33%). At the dose of 5 mg/day the treatment was well tolerated. Neutropenia grade 4 was present in only 6% of patients; alopecia > grade 1 and cardiotoxicity did not occur. The median time to progression was 3 months and the median overall survival was 17 months. IDA Ctrough and IDOL Ctrough levels were significantly associated with haematologic toxicity. Conclusion: This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. A determination of the IDA and IDOL plasma levels (Ctrough) is predictive for toxicity.

AB - Background: To determine if protracted low-dose oral idarubicin (IDA), feasible in a previous dose-finding study, would result in similar activity and a better toxicity profile in patients with metastatic breast cancer. Patients and methods: Elderly women (≥65 years) with metastatic breast carcinoma were treated with 7.5 mg/day for 21 consecutive days, every 4 weeks. After the first fourteen patients, due to excessive toxicity, the protocol was amended to 5 mg/day. IDA and Idarubicinol (IDOL) plasma concentrations (Ctrough) were investigated in all patients. Results: Between April 1999 and June 2004, 47 elderly patients were accrued in this two-part study (14 and 33 patients respectively). The median age was 74 and 75 years respectively. Visceral involvement was present in most patients. A partial response was noted in 7/31 patients (22%; 95% CI, 9.6-41.1%). Eleven patients had stable disease (33%). At the dose of 5 mg/day the treatment was well tolerated. Neutropenia grade 4 was present in only 6% of patients; alopecia > grade 1 and cardiotoxicity did not occur. The median time to progression was 3 months and the median overall survival was 17 months. IDA Ctrough and IDOL Ctrough levels were significantly associated with haematologic toxicity. Conclusion: This study shows that idarubicin at the dose of 5 mg/day for 21 consecutive days is feasible and effective in elderly breast cancer patients but do not demonstrate an improvement in efficacy. A determination of the IDA and IDOL plasma levels (Ctrough) is predictive for toxicity.

KW - Elderly breast cancer patients

KW - Oral idarubicin

UR - http://www.scopus.com/inward/record.url?scp=33646202671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646202671&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl013

DO - 10.1093/annonc/mdl013

M3 - Article

C2 - 16497825

AN - SCOPUS:33646202671

VL - 17

SP - 807

EP - 812

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -